Table 1

Characteristics of 204 patients with ankylosing spondylitis in western Sweden

Patients,

number (%)

Median (range)

Mean ± SD


Demographic variables

Sex

Women

87 (43)

Men

117 (57)

Age, years

NA

49 (17 to 78)

50 ± 13

Postmenopausal women

45/87 (52)

Heredity for fractures

57 (28)

History of vertebral fracture

3 (1)

History of non-vertebral fracture

18 (9)

Current smokers

24 (12)

Ever smoked > 6 months

101 (50)

Daily calcium intake from dairy products

NA

600 (0 to 2,640)

668 ± 397

BMI, kg/m2

25 (19 to 46)

26 ± 4

LTPAI total, hours

6 (0 to 42)

7 ± 6

PAHWI total, hours

45 (0 to 160)

40 ± 21

FRAX major osteoporotic fracture (%)

(patients ≥ 40 years)

6.7 (1.2 to 68.0)

9.9 ± 9.7

FRAX hip fracture (%)

(patients ≥ 40 years)

0.8 (0 to 56.0)

2.4 ± 6.0

Disease-related variables

Years since onset of symptoms

24 (2 to 55)

24 ± 13

Years since diagnosis

12 (1 to 47)

15 ± 11

History of anterior uveitis

102 (50)

History of peripheral arthritis

120 (59)

History of coxitis

17 (8)

BASMI, score

3.0 (0.6 to 7.4)

3.1 ± 1.6

BASDAI, score

3.5 (0.0 to 9.6)

3.6 ± 2.1

BASFI, score

2.3 (0.0 to 8.7)

2.7 ± 2.1

BAS-G1, score (last week)

2.9 (0.0 to 10.0)

3.4 ± 2.6

BAS-G2, score (last 6 months)

3.4 (0.0 to 9.7)

3.8 ± 2.6

ASDAS, score

2.3 (0.8 to 5.9)

2.4 ± 0.9

mSASSS, score

5.5 (0.0 to 72.0)

14.2 ± 19.2

Mean ESR, mm/h (2004 to 2008)

16 (2 to 102)

19 ± 15

ESR, mm/h (at inclusion 2009)

11 (2 to 105)

15 ± 14

CRP, mg/L

5 (3 to 80)

9 ± 10

Hemoglobin, g/L

139 (105 to 166)

139 ± 13

WBC, × 109/L

6.7 (2.7 to 18.1)

7.0 ± 2.1

PLT, × 109/L

287 (133 to 506)

299 ± 75

Creatinine, μmol/L

70 (43 to 148)

71 ± 15

HLA-B27 positive

178 (87)

Patients on NSAID

158 (77)

Patients on DMARD

62 (30)

Patients on TNF inhibitor

42 (21)

Patients on GC

7 (3)

GC lifetime use, mg prednisone

NA

100 (0, 56390)

1397 ± 5775

Patients on bisphosphonates

8 (4)

Patients on HRT

5 (2)

Patients on calcium and vitamin D

24 (12)

Bone mineral density

aBMD AP lumbar spine, g/cm2

1.02 (0.63 to 1.54)

1.02 ± 0.17

aBMD lateral lumbar spine, g/cm2

0.72 (0.32 to 1.13)

0.73 ± 0.14

vBMD lumbar spine, g/cm3

0.19 (0.09 to 0.27)

0.19 ± 0.03

BMD total hip, g/cm2

0.93 (0.54 to 1.42)

0.94 ± 0.14

BMD femoral neck, g/cm2

0.78 (0.48 to 1.20)

0.78 ± 0.13

BMD radius total, g/cm2

0.61 (0.40 to 0.78)

0.61 ± 0.08


BMI, body mass index; LTPAI, Leisure Time Physical Activity Instrument; PAHWI, Physical Activity at Home and Work Instrument; FRAX, World Health Organization Fracture Risk Assessment Tool (% 10 year probability of major osteoporotic, and vertebral fracture respectively, corresponding to patients aged 40 years or older); BASMI, Bath Ankylosing Spondylitis Metrology Index; BASDAI, Bath Ankylosing Spondylitis Disease Activity Index; BASFI, Bath Ankylosing Spondylitis Functional Index; BAS-G1 and G2, Bath Ankylosing Spondylitis Patient Global Score; ASDAS, ankylosing spondylitis disease activity score; mSASSS, modified Stoke Ankylosing Spondylitis Spine Score; ESR, erythrocyte sedimentation rate; CRP, C-reactive protein; PLT, platelet count; WBC, white blood cell count; NSAID, non-steroidal anti-inflammatory drug; DMARD, disease modifying anti-rheumatic drug; TNF, tumour necrosis factor; GC, glucocorticoid; HRT, hormone replacement therapy; aBMD, areal bone mineral density; AP, anteroposterior; vBMD, volumetric BMD

Klingberg et al. Arthritis Research & Therapy 2012 14:R108   doi:10.1186/ar3833

Open Data